You are here

Article info

Article menu
Download PDFPDF
Letter
ADAMTS5 as a therapeutic target for osteoarthritis: Mendelian randomisation study

Authors

  • Sizheng Steven Zhao Centre for Epidemiology Versus Arthritis, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Ville Karhunen Research Unit of Mathematical Sciences, University of Oulu, Oulu, Finland Center for Life Course Health Research, University of Oulu, Oulu, Finland PubMed articlesGoogle scholar articles
  • Andrew P Morris Centre for Genetics and Genomics Versus Arthritis, University of Manchester, Manchester, UK PubMed articlesGoogle scholar articles
  • Dipender Gill Clinical Pharmacology and Therapeutics Section, Institute for Infection and Immunity, St George’s, University of London, London, UK Clinical Pharmacology Group, Pharmacy and Medicines Directorate, St George’s University Hospitals NHS Foundation Trust, London, UK Department of Epidemiology and Biostatistics, Imperial College London, London, UK PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Sizheng Steven Zhao, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Science, Stopford Building, University of Manchester, Oxford Road, Manchester, M13 9PT, UK; sizheng.zhao{at}manchester.ac.uk
View Full Text

Citation

Zhao SS, Karhunen V, Morris AP, et al
ADAMTS5 as a therapeutic target for osteoarthritis: Mendelian randomisation study
Annals of the Rheumatic Diseases 2022;81:903-904.

Publication history

  • Received December 15, 2021
  • Accepted January 25, 2022
  • First published February 7, 2022.
Online issue publication 
October 18, 2023

Copyright information

© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.